Perinatal Anxiety and Depression: Weighing Treatment Against Untreated Illness
A 29-year-old woman at 22 weeks' gestation presents with 6 weeks of persistent worry, initial insomnia, palpitations, and intrusive thoughts that something will happen to the baby. GAD-7 is 15; PHQ-9 is 12 with no suicidal ideation. She has a history of one major depressive episode at age 25 that remitted with sertraline 50 mg, which she stopped 2 years ago. She is tearful and asks, 'Is it safer to just stop everything and tough it out for the baby?' She has no prior perinatal complications, is in a stable relationship, and has an engaged partner. She is not currently on medication.
1. How do you frame the risk-benefit discussion, and what does the evidence say about untreated perinatal anxiety/depression versus treatment?
Read the worked answer
Frame the decision as 'untreated illness carries real risk' - not 'medication versus nothing.'
Risks of untreated perinatal anxiety/depression:
- Maternal: poor self-care, inadequate nutrition/prenatal care, insomnia, worsening depression, and postpartum relapse risk.
- Fetal/neonatal: associated with preterm birth and low birth weight; chronic stress and cortisol effects are implicated.
- Postnatal: impaired bonding, and risks to infant development and attachment.
- Safety: the PHQ-9 is currently 12 without SI, but untreated illness can escalate; ongoing monitoring is essential.
Evidence framing:
- SSRIs are among the most studied medications in pregnancy; sertraline has a large body of data and is often favored. Absolute risks of major malformations are generally not substantially elevated for SSRIs as a class, though some agents carry specific signals (e.g., paroxetine and cardiac defects; persistent pulmonary hypertension of the newborn is a rare absolute risk).
- Third-trimester exposure can cause transient neonatal adaptation symptoms (jitteriness, feeding difficulty) that are usually self-limited.
- The comparison is not risk-free: untreated illness has its own documented maternal and fetal harms.
Key counseling point: For a woman with a prior response to sertraline and moderate current symptoms, restarting an effective, well-studied agent - paired with psychotherapy - is a reasonable and often preferred option, decided collaboratively and documented.
2. Outline a treatment and monitoring plan, including nonpharmacologic components and postpartum considerations.
Read the worked answer
Plan:
- Shared decision-making documented: discuss sertraline restart (start low, e.g., 25-50 mg, titrate to response) versus psychotherapy-first for milder symptoms; given moderate severity and prior response, combined treatment is reasonable.
- Psychotherapy: CBT is first-line for perinatal anxiety and has no fetal risk; refer concurrently.
- Sleep and behavioral supports: address initial insomnia with sleep hygiene and behavioral strategies; avoid relying on sedative-hypnotics in pregnancy.
- Monitoring: reassess GAD-7/PHQ-9 regularly, screen for SI at each visit, and watch for escalation; coordinate with obstetric care.
- Postpartum planning (start before delivery):
- Relapse risk is highest postpartum - plan continued treatment and close follow-up.
- Screen for postpartum depression and postpartum psychosis (the latter is a psychiatric emergency).
- Discuss breastfeeding compatibility (sertraline is generally considered a preferred SSRI in lactation).
- Arrange support and a safety plan with the partner.
Exam-tested judgment: Do not default to 'stop everything for the baby.' Weigh documented risks of untreated illness against a well-studied medication, treat moderate symptoms actively, and build a postpartum relapse-prevention plan before delivery.